| Name | Title | Contact Details |
|---|---|---|
Ashwin Altekar |
Vice President of Information Security | Profile |
Accretive Health utilizes over a decade of operational expertise to bring measured impact to healthcare providers. We partner with hospitals and health systems to implement proprietary methodologies and relieve administrative burdens, allowing them to focus on their core mission: delivering high-quality care. Accretive Health’s operational framework centers on demonstrated capabilities and proficiencies across the end-to-end revenue cycle. Our solutions translate proven tactics and processes into measurable impact, leading to superior financial and organizational outcomes. Accretive Health utilizes over a decade of operational expertise to bring measured impact to healthcare providers. We partner with hospitals and health systems to implement proprietary methodologies and relieve administrative burdens, allowing them to focus on their core mission: delivering high-quality care. Accretive Health’s operational framework centers on demonstrated capabilities and proficiencies across the end-to-end revenue cycle. Our solutions translate proven tactics and processes into measurable impact, leading to superior financial and organizational outcomes.
MedicineNet is a San Clemente, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bonfils Blood Center Foundation was established in 1995 as the fundraising arm of Bonfils Blood Center and serves the core function of encouraging and managing philanthropy to support a variety of programs and initiatives for Bonfils Blood Center. From
URAC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Repertoire Immune Medicines is working to unleash the remarkable power of the human immune system to prevent, treat or cure cancer, autoimmune conditions, and infectious diseases. Repertoire scientists created and developed a suite of technologies for its DECODE discovery and DEPLOY product platforms that allow in-depth characterization of the immune synapse and the ability to rationally design, and clinically develop, multi-clonal immune medicines. The company is currently conducting experimental medicine clinical trials using autologous T cells primed against cancer antigens and tethered to IL-15.